Authors
Loading...
Clinical review reveals cardiovascular benefits and vascular risks of erythropoietin in dialysis patients, highlighting the need to balance anaemia correction against adverse effects.
LEE et al. (1996) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: